BOSTON, Jan. 16, 2026 (GLOBE NEWSWIRE) — Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana”), a biotechnology company developing its lead candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, announces the closing of its previously announced Company best efforts registered direct offering (“Offering”) of 7,040,000 ordinary shares at an offering price of $1.25 per ordinary share conducted without an underwriter or placement agent to members of senior management and existing shareholders. The gross proceeds to Tiziana from the Offering, before deducting estimated Offering expenses payable by Tiziana, were $8.8 million. For every ordinary share subscribed, participants will receive one warrant entitling the holder to subscribe for one new ordinary share at a price of $1.50 at any time up to and...

MELBOURNE, Australia, Jan. 17, 2026 (GLOBE NEWSWIRE) — Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces that the first patient in the United States (U.S.) has been dosed in BiPASS™ (Biopsy of the Prostate Avoidance Stratification Study), a Phase 3 trial to evaluate the use of Telix’s commercial PSMA-PET1 imaging agents, Illuccix® (kit for the preparation of gallium Ga 68 gozetotide injection) and Gozellix® (kit for the preparation of gallium Ga 68 gozetotide injection) in the initial prostate cancer diagnosis setting. The dose was administered under the supervision of Dr. Brian Mazzarella at Urology Austin and supplied by RLS Radiopharmacies. BiPASS™ is the first study designed to gain marketing authorization for 68Ga-PSMA-PET2 imaging in the pre-biopsy setting. The prospective, open-label...

Company AnnouncementBased on the topline results from the EPCORE® DLBCL-1 trial, Genmab will engage global regulatory authorities to discuss next stepsCOPENHAGEN, Denmark; January 16, 2026 – Genmab A/S (Nasdaq: GMAB) today announced topline results from the Phase 3 EPCORE DLBCL-1 trial evaluating epcoritamab, a T-cell engaging bispecific antibody administered subcutaneously, which demonstrated an improvement in progression-free survival (PFS) (HR: 0.74 [95% CI 0.60 to 0.92])* in patients treated with epcoritamab monotherapy. Additionally, improvements were observed in the complete response rate, duration of response, and time to next treatment among patients treated with epcoritamab monotherapy. EPCORE DLBCL-1 is the first Phase 3 study to demonstrate an improvement in PFS in patients with relapsed or refractory (R/R) diffuse large...

Partner Status empowers UK organisations to harness advanced digital capabilities without compromising sovereignty, security or sustainability LONDON, Jan. 16, 2026 (GLOBE NEWSWIRE) —  Rackspace Technology® (NASDAQ: RXT), a leading end-to-end hybrid cloud and AI solutions company, today announced its UK Sovereign Services has achieved the VMware Sovereign Cloud Partner Status, reinforcing Rackspace’s ability to store, process, and protect UK organisations’ most sensitive data. Rackspace Sovereign Services delivers a fully managed, private cloud platform designed specifically for organisations that require strict control over where data is located and how it is processed. Built on proven VMware technologies and operated from UK-based data centres, the service combines high availability, resilient networking, and integrated security...

Aspo Plc  ANNOUNCEMENT  16.1.2026          Aspo Plc: Share repurchase 16.1.2026       In the Helsinki Stock Exchange         Trade date           16.1.2026  Bourse trade         Buy  Share                  ASPO  Amount             1 000 SharesAverage price/ share    7,2400 EURTotal cost            7 240,00 EUR          Aspo Plc now holds a total of 120 552 shares  including the shares repurchased on 16.1.2026       The share buybacks are executed in compliance with Regulation No. 596/2014 of the European Parliament and Council (MAR) Article 5and the Commission Delegated Regulation (EU) 2016/1052.          On behalf of Aspo Plc         Nordea Bank Oyj              Sami Huttunen Ilari Isomäki       For more information, please contact:  Erkka Repo,...

Elis announces the termination of the liquidity contract Puteaux, 16 January 2026 – Elis, the global leader in circular services at work, announces the termination of the liquidity contract agreed on December 1, 2023 with Oddo BHF (Group Natixis). The contract had been suspended since January 9, 2026, and was terminated by Elis with effect from January 14, 2026, in connection with the continuation of its share buyback program. As of January 14, 2026, the following resources appeared on the liquidity account:115,913 shares €3,197,794During the period from January 1, 2026 to January 8, 2026, the following resources were traded:On buy side, 48,667 shares for €1,174,141 (85 executions) On sell side, 64,304 shares for €1,562,380 (149 executions)As a reminder: 1)   The following resources appeared on the second half year statement...

Oslo, 16 January 2026: Scatec ASA will release its fourth quarter results on Friday 30 January 2026 at 07:00 CET. A presentation followed by a Q&A session will be held on the same day at 09:00 CET at Scatec’s headquarters at Skøyen Atrium III (1st floor), Askekroken 11, 0277 Oslo. The presentation and the Q&A session can be followed through a live webcast: Scatec webcast Q4 2025. For further information, please contact:For analysts and investors:Andreas Austrell, SVP IRandreas.austrell@scatec.com+47 974 38 686 For media:Meera Bhatia, SVP External Affairs & Communicationsmeera.bhatia@scatec.com+47 468 44 959 About Scatec  Scatec is a leading renewable energy solutions provider, accelerating access to reliable and affordable clean energy in emerging markets. As a long-term player, we develop, build, own, and operate renewable...

Kering – Statement Number of Shares and voting rights – 15.01.2026  KeringSociété anonyme with a share capital of €493,683,112Head office: 40, rue de Sèvres – 75007 PARIS552 075 020 RCS PARIS January 16, 2026 Monthly statement on the total number of shares and voting rights(articles L.233-8 of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (AMF – Autorité des Marchés Financiers)Date     Total number ofshares   Total number of voting rightstheoretical 1 exercisable 2January 15, 2026 123,420,778 176,681,841 175,881,0141 Calculated based on all shares with voting rights, including treasury shares stripped of voting rights (Art. 223-11 of AMF General Regulation). 2 Excluding treasury shares stripped of voting rights.AttachmentKering –...

The Great American Food Chain, Inc. Announces Execution of Memorandum of Understanding with Green Matter BioTech DALLAS, Jan. 16, 2026 (GLOBE NEWSWIRE) — The Great American Food Chain, Inc. (OTC: GAMN) (“GAMN” or the “Company”) announced today that it has executed a Memorandum of Understanding (“MOU”) with Green Matter BioTech, Inc. (“Green Matter”) outlining the parties’ mutual intent to pursue a potential business combination transaction. The MOU is non-binding and reflects the parties’ current intent to continue discussions and conduct customary due diligence. Any proposed transaction remains subject to the negotiation and execution of definitive agreements, completion of due diligence, receipt of any required approvals, and satisfaction of other customary closing conditions. There can be no assurance that a definitive agreement...

Reiterates Commitment to Enhancing Shareholder Value Reiterates Benefits of Genco Acquiring Diana for Creating Value for Both Company Shareholders No Shareholder Action Required at This Time NEW YORK, Jan. 16, 2026 (GLOBE NEWSWIRE) — Genco Shipping & Trading Limited (NYSE:GNK) (“Genco” or the “Company”), the largest U.S. headquartered drybulk shipowner focused on the global transportation of commodities, today responded to Diana Shipping Inc. (“Diana”), which disclosed its intent to nominate six director candidates to stand for election to the Genco Board of Directors at the Company’s 2026 Annual Meeting of Shareholders (the “2026 Annual Meeting”). Genco issued the following statement: Our Board is dedicated to upholding the highest standards for corporate governance to further its fiduciary duties. In that light, the Board...